Wegovy is designed to be injected once a week, on the same day each week, and its prescribing information gives you a specific window if you miss that day: take your shot as soon as you remember, as long as it has been fewer than five days since you were supposed to inject. If five or more days have passed, skip that dose entirely and pick up on your next regularly scheduled day. This flexibility comes from semaglutide’s relatively long half-life of about seven days, which keeps meaningful drug levels in your blood even when you’re a bit late. But the cushion is not unlimited, and understanding what happens during and after a gap matters more than most people realize.
The Five-Day Rule and Why It Exists
Semaglutide, the active ingredient in Wegovy, circulates in your body far longer than most injected medications. With a half-life around seven days, roughly half the drug is still present a full week after injection, and it takes about five weeks of consistent weekly dosing for levels to fully stabilize. That slow buildup and slow clearance is what makes a once-weekly injection possible in the first place and is also what gives you a buffer when life gets in the way.
The five-day window in the prescribing information is a practical cutoff. If you normally inject on Monday and remember on Thursday, you still have enough time for the drug to integrate into your weekly rhythm without doubling up or creating an awkward overlap with next week’s dose. But if you don’t remember until the following Sunday, injecting would place two doses uncomfortably close together, since your next scheduled shot is the very next day. In that scenario, the guidance is simple: skip the late dose, inject on Monday as planned, and continue your regular schedule from there.
What Missing a Single Dose Actually Feels Like
Because the drug clears slowly, missing one shot rarely causes a dramatic shift. You won’t suddenly feel ravenous the morning after a missed dose. Blood levels drop gradually, so most people report that the first few days feel essentially normal. By the end of the second week without a dose, though, you may notice appetite creeping back or food starting to occupy more mental space again.
Part of what Wegovy does is slow down how quickly your stomach empties after a meal, which contributes to feeling full longer. Research on semaglutide’s mechanism shows that this gastric emptying delay is driven by activation of receptors in the gut and signaling through the vagus nerve, and that the effect can be strongest during the dose-escalation phase before somewhat diminishing with chronic use.1Journal of International Research in Medical and Pharmaceutical Sciences. From Gut to Brain: The Neurohormonal Basis of Appetite Suppression and Gastric Emptying Delay by Semaglutide in Non-Diabetic Obesity When the drug level drops after a missed dose, gastric motility speeds back up relatively quickly, and that “I could skip lunch without thinking about it” feeling fades. For many people, the appetite-suppressing effects in the brain take a bit longer to fully unwind than the stomach effects do, so the experience of a short gap is usually subtle rather than jarring.
Gaps Longer Than Two Weeks
If you go two weeks or more without an injection, you’re entering territory where the drug has cleared enough that your body is functionally off treatment. When you restart after a gap of this length, your prescriber will usually recommend going back to a lower dose rather than jumping straight to where you left off. This isn’t arbitrary caution. The dose-escalation schedule exists because semaglutide’s most common side effects, particularly nausea and vomiting, hit hardest when the body hasn’t adjusted to a given dose. Restarting at your maintenance dose after a multi-week gap is essentially exposing a drug-naive gut to a high dose, which can trigger significant gastrointestinal distress.
The standard titration schedule for Wegovy starts at 0.25 mg weekly for four weeks, then increases monthly through 0.5 mg, 1 mg, and 1.7 mg before reaching the target dose of 2.4 mg. If your gap was only two to three weeks, some prescribers will restart one step below your previous dose rather than going all the way back to the beginning. There’s no universal protocol for this, so the conversation with your doctor matters. The key point is that a longer gap doesn’t just delay your progress; it resets some of the tolerance your body built, and trying to power through that reset by resuming at full dose usually backfires with side effects.
What Happens If You Stop Entirely
The question of going between shots blurs into a bigger question many people have: what happens when you stop altogether? The evidence here is clear and somewhat sobering. In the extension of the landmark STEP 1 trial, participants who stopped semaglutide after 68 weeks regained about two-thirds of the weight they had lost over the following year, with an average regain of nearly 12 percentage points of body weight. Most of the improvements in blood pressure, cholesterol, and blood sugar that had accumulated during treatment also reverted toward where they started.2PubMed Central. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Real-world data paints a more varied picture. A large study of clinical practice found that among people taking semaglutide for obesity, the average weight change in the year after stopping was only about half a percent of regain, far less than the trial data would predict. But the researchers noted considerable individual variability: some people regained substantially, while others maintained their losses or even continued losing weight, often because they switched to another medication or made lasting behavioral changes.3PubMed Central. Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide The takeaway is that stopping semaglutide doesn’t guarantee a full rebound, but the biological pressure to regain weight is strong, and most people need some ongoing strategy to counteract it.
Early Versus Late Discontinuation
Timing matters. Not all treatment gaps are equal, and people who stop early in the process fare differently than those who reach the maintenance dose before discontinuing. A study examining semaglutide outcomes by discontinuation timing found that people who stopped early averaged only about a 4% weight reduction at one year, compared with nearly 12% for those who stayed on treatment without interruption.4PubMed Central. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status People who discontinued later, after reaching higher doses, fell somewhere in between.
This pattern makes sense when you consider how the drug works. The dose-escalation months aren’t just about tolerating side effects; they’re the period where the drug is building to a therapeutically effective concentration. Stopping during escalation means you never got the full benefit. It also means the side effects you pushed through during those early weeks didn’t pay off in the way they would have had you continued. If you’re considering pausing treatment during the ramp-up phase, this is worth discussing honestly with your prescriber, because the math on restarting later isn’t especially favorable.
Why People End Up With Gaps in the First Place
Understanding the pharmacology of missed doses is helpful, but it glosses over the messier reality that many people don’t choose to skip a dose. Gaps happen because of cost, supply interruptions, insurance paperwork, and side effects that become intolerable. Research on adherence to GLP-1 medications identifies gastrointestinal symptoms during dose escalation as the most common medical reason people stop, while high out-of-pocket costs and inconsistent insurance coverage are the most common financial ones. In settings without subsidized coverage, long-term persistence with these medications drops below 10%.5Saudi Journal of Medicine and Public Health. Factors Influencing Adherence to GLP-1 Receptor Agonist Therapy Among Patients Receiving Weight-Loss Injections
Among commercially insured adults in the United States, nearly half of those who started Wegovy had discontinued by the fifth month. The biggest predictor of dropping off wasn’t a medical complication; it was the monthly copayment. People in the highest copay bracket were roughly a quarter more likely to stop than those paying the least out of pocket.6PubMed Central. Titration and discontinuation of semaglutide for weight management in commercially insured US adults Lower household income and lower education levels were also linked to higher discontinuation, painting a picture where the people who could benefit most from sustained treatment are least likely to maintain access to it.
Insurance authorization adds another layer. Most plans that cover Wegovy approve it for three to six months at a time and require documentation of at least 5% weight loss from baseline for renewal. If the reauthorization isn’t submitted well in advance, a lapse in approval can create a one-to-three-week gap in access while paperwork processes. That forced gap is long enough to drop drug levels and potentially trigger a dose adjustment when you restart, turning an administrative delay into a clinical setback.
Traveling Across Time Zones
Travel is one of the more common practical reasons people wonder about dose timing. If you fly from New York to Tokyo, your “every Monday” schedule suddenly lands on a different calendar day depending on how you count. The good news is that the seven-day half-life gives you real flexibility here. Shifting your injection by a day or two in either direction to accommodate travel is pharmacologically trivial. Your blood levels won’t meaningfully change if you inject on Saturday instead of Monday for one week, then return to Monday the following week.
The more important concern when traveling is storage. Wegovy pens that haven’t been used should be refrigerated between 36°F and 46°F (2°C to 8°C). Once you start using a pen, it can be kept at room temperature (up to 86°F / 30°C) for up to 28 days. On a long flight or in a hot climate, a small insulated pouch with a cool pack is enough to keep the pen safe. Do not freeze it, and do not leave it in a checked bag in the cargo hold of a plane, where temperatures can drop well below freezing.
If your trip is long enough that the time-zone math gets confusing, a simple approach is to track your injections by the number of hours between doses rather than by the day of the week. Aim for roughly 168 hours (seven days) between shots, give or take a day, and adjust your “regular day” once you’re settled in the new time zone. If a longer gap is genuinely unavoidable because of itinerary logistics, the same five-day-late rule applies while traveling as it does at home.
Restarting After a Supply Interruption
Wegovy experienced well-publicized supply shortages that left many patients unable to fill prescriptions for weeks or months at a time. When supply returned, patients and prescribers faced the question of how to safely resume. The general approach mirrors what happens after any extended gap: start lower on the dose ladder and titrate back up, though the pace can sometimes be faster the second time around since the body has some residual familiarity with the drug’s effects.
During shortages, some patients turned to compounded versions of semaglutide, which are prepared by compounding pharmacies rather than Novo Nordisk. These formulations are not FDA-approved, and quality concerns are real. An analysis of compounded semaglutide products found that follow-on injectable versions contained new impurities and different impurity patterns compared to the branded drug, including high molecular weight proteins and trace metals. Some compounded oral versions contained markedly less semaglutide than their labels claimed, and dissolution testing showed different drug-release profiles that could reduce how much of the medication your body actually absorbs.7Pharmaceutical Research. Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs
The practical concern isn’t just theoretical purity. If a compounded product delivers an unpredictable amount of semaglutide per dose, you lose the ability to trust that your weekly injection is keeping blood levels stable. You might get more than expected one week and less the next, which makes side effects harder to predict and appetite control less consistent. For someone bridging a short gap in branded supply, these risks might seem acceptable. For someone using compounded semaglutide as a long-term alternative, the inconsistency compounds over time.
How Consistent Dosing Drives Results in Trials
It’s worth noting that the headline weight-loss numbers you see in Wegovy’s clinical trials reflect what happens with near-perfect adherence. In the STEP 12 trial, for example, participants receiving semaglutide 2.4 mg weekly for the full study duration lost an average of about 12% of their body weight, compared with roughly 2% in the placebo group. About 80% of those on semaglutide achieved at least 5% weight loss.8The Lancet Diabetes & Endocrinology. Efficacy and safety of once-weekly semaglutide 2·4 mg in adults with overweight or obesity in mainland China and Taiwan (STEP 12) These results come from closely monitored participants who rarely missed a dose. In the real world, where gaps happen routinely for all the reasons described above, the average outcome is more modest. That gap between trial efficacy and real-world effectiveness is one of the most persistent challenges in obesity medicine.
This doesn’t mean every missed dose erases your progress. The drug’s long half-life is deliberately engineered to be forgiving. But consistency over months is what separates the people who get close to trial-level results from those who see only partial benefit. If you know a gap is coming, whether from travel, a prescription lapse, or a planned surgery that requires pausing the medication, working with your prescriber to manage the interruption proactively is almost always better than figuring it out afterward.
Dose Stretching and Off-Label Spacing
Some patients and online communities discuss “stretching” doses by injecting every ten days or every two weeks instead of weekly, either to save money or to manage side effects. This is not how the drug was studied, and there’s no published clinical evidence supporting alternative dosing intervals for semaglutide at the 2.4 mg weight-management dose. The pharmacokinetics don’t necessarily prohibit it: with a seven-day half-life, injecting every ten days would still maintain some drug in your system. But the steady-state concentration would be lower, and the peaks and troughs between injections would be more pronounced. Whether that translates to meaningfully less appetite suppression or just a minor reduction isn’t something anyone has formally tested.
Prescribers who are aware that their patients are stretching doses generally prefer to discuss lowering the dose instead. Staying on a lower but consistent weekly dose maintains the stable blood levels the drug was designed around, while reducing cost per month if you’re paying out of pocket (since lower-dose pens are sometimes less expensive, depending on pharmacy pricing). It also avoids the psychological trap of a variable schedule, where you forget whether this is a seven-day week or a ten-day week and end up with unintentional gaps on top of intentional ones.
The honest picture is that semaglutide’s long half-life makes it more forgiving of timing imperfections than almost any other injectable medication people take at home. Being a day late is nothing. Being two or three days late is manageable. Going beyond five days late means skipping that dose and getting back on track the following week. And stopping entirely, whether for weeks or months, comes with a real likelihood of weight regain that accelerates the longer treatment stays paused. The drug works well when it’s in your system at reliable levels, and the weekly schedule is the simplest way to keep it there.